Cyproterone Acetate Loading to Lipid Nanoparticles
999
12. M. J. Choi and H. I. Maibach. Liposomes and niosomes as
topical drug delivery systems. Skin Pharmacol. Physiol.
18:209Y219 (2005).
13. M. Scha¨fer-Korting, W. Mehnert, and H. C. Korting. Lipid
nanoparticles for improved topical application of drugs for skin
diseases. Adv. Drug Deliv. Rev. (in press).
14. E. Bernard, J. L. Dubois, and J. Wepierre. Importance of
sebaceous glands in cutaneous penetration of an antiandrogen:
target effect of liposomes. J. Pharm. Sci. 86:573Y578 (1997).
15. D. M. Gruber, M. O. Sator, E. A. Joura, E. M. Kokoschka,
G. Heinze, and J. C. Huber. Topical cyproterone acetate treatment
in women with acne: a placebo-controlled trial. Arch. Dermatol.
134:459Y463 (1998).
16. U. Mu¨nster, C. Nakamura, A. Haberland, K. Jores, W. Mehnert,
S. Rummel, M. Schaller, H. C. Korting, C. Zouboulis, U. Blume-
Peytavi, and M. Scha¨fer-Korting. RU 58841-myristate-prodrug
development for topical treatment of acne and androgenetic
alopecia. Pharmazie 60:8Y12 (2005).
was described when 20 tape strips were taken (44,45), we failed
to detect an improved CPA uptake by this approach which is
reported to remove the horny layer by about 50% (44). Yet this
appears to be less under our experimental conditions. Thus, the
influence of skin damage on CPA absorption needs further
studies.
CONCLUSION
Given that CPA loading to nanoparticulate carrier sys-
tems or microspheres enhancing skin absorption results in
therapeutic drug levels within the target tissue while reducing
systemic availability of the antiandrogen as compared to the
oral route, this may stimulate the development of a commer-
cial topical formulation.
17. G. Cevc. Lipid vesicles and other colloids as drug carriers on the
skin. Adv. Drug Deliv. Rev. 56:675Y711 (2004).
18. A. A. Date, B. Naik, and M. S. Nagarsenker. Novel drug
delivery systems: potential in improving topical delivery of
antiacne agents. Skin Pharmacol. Physiol. 19:2Y16 (2006).
19. C. Freitas and R. H. Mu¨ller. Stability determination of solid lipid
nanoparticles (SLN) in aqueous dispersion after addition of
electrolyte. J Microencapsul. 16:59Y71 (1999).
ACKNOWLEDGEMENT
Financial support of the Deutsche Forschungsge-
meinschaft, FG 463 (SCHA 382, KR 1696), is gratefully 20. V. Jenning, A. F. Thunemann, and S. H. Gohla. Characterisation
of a novel solid lipid nanoparticle carrier system based on binary
acknowledged.
mixtures of liquid and solid lipids. Int. J. Pharm. 199:167Y177 (2000).
21. B. Siekmann and K. Westesen. Sub-micron sized parenteral
carrier systems based on solid lipid. Pharm. Pharmacol. Lett.
1:123Y126 (1992).
22. A. zur Mu¨hlen, C. Schwarz, and W. Mehnert. Solid lipid nano-
particles (SLN) for controlled drug delivery-drug release and
REFERENCES
1. W. F. Bergfeld. The evaluation and management of acne: economic
considerations. J. Am. Acad. Dermatol. 32:S52YS56 (1995).
release mechanism. Eur. J. Pharm. Biopharm. 45:149Y155 (1998).
23. R. H. Mu¨ller, M. Radtke, and S. A. Wissing. Solid lipid
nanoparticles (SLN) and nanostructured lipid carriers (NLC)
in cosmetic and dermatological preparations. Adv. Drug Deliv.
Rev. 54(Suppl 1):S131YS155 (2002).
24. S. Lombardi-Borgia, M. Regehly, R. Sivaramakrishnan,
W. Mehnert, H. C. Korting, K. Danker, B. Ro¨der, K. D. Kramer,
and M. Scha¨fer-Korting. Lipid nanoparticles for skin penetration
enhancement-correlation to drug localization within the particle
matrix as determined by fluorescence and parelectric spectrosco-
py. J. Control. Release 110:151Y163 (2005).
25. C. Santos Maia, W. Mehnert, M. Schaller, H. Korting, A. Gysler,
A. Haberland, and M. Scha¨fer-Korting. Drug targeting by solid
lipid nanoparticles for dermal use. J. Drug Target. 10:489Y495
(2002).
26. R. Sivaramakrishnan, C. Nakamura, W. Mehnert, H. C. Korting,
K. D. Kramer, and M. Scha¨fer-Korting. Glucocorticoid entrap-
ment into lipid carriers-characterisation by parelectric spectros-
copy and influence on dermal uptake. J. Control. Release
97:493Y502 (2004).
2. H. Akamatsu, C. C. Zouboulis, and C. E. Orfanos. Control
of human sebocyte proliferation in vitro by testosterone and
5-alpha-dihydrotestosterone is dependent on the localization of
the sebaceous glands. J. Invest. Dermatol. 99:509Y511 (1992).
3. M. Fritsch, C. E. Orfanos, and C. C. Zouboulis. Sebocytes are the
key regulators of androgen homeostasis in human skin. J. Invest.
Dermatol. 116:793Y800 (2001).
4. Y. Ando, Y. Yamaguchi, K. Hamada, K. Yoshikawa, and S. Itami.
Expression of mRNA for androgen receptor, 5alpha-reductase
and 17beta-hydroxysteroid dehydrogenase in human dermal
papilla cells. Br. J. Dermatol. 141:840Y845 (1999).
5. D. Van Neste. Natural scalp hair regression in preclinical stages
of male androgenetic alopecia and its reversal by finasteride.
Skin Pharmacol. Physiol. 19:168Y176 (2006).
6. D. Van Neste, V. Fuh, P. Sanchez-Pedreno, E. Lopez-Bran,
H. Wolff, D. Whiting, J. Roberts, D. Kopera, J. J. Stene, S. Calvieri,
A. Tosti, E. Prens, M. Guarrera, P. Kanojia, W. He, and K. D.
Kaufman. Finasteride increases anagen hair in men with
androgenetic alopecia. Br. J. Dermatol. 143:804Y810 (2000).
7. W. A. van Vloten, C. W. van Haselen, E. J. van Zuuren, C.
Gerlinger, and R. Heithecker. The effect of 2 combined oral
27. R. M. Hoffman. Topical liposome targeting of dyes, melanins,
genes, and proteins selectively to hair follicles. J. Drug Target.
5:67Y74 (1998).
contraceptives containing either drospirenone or cyproterone 28. J. Lademann, H. Weigmann, C. Rickmeyer, H. Barthelmes,
acetate on acne and seborrhea. Cutis 69:2Y15 (2002).
H. Schaefer, G. Mueller, and W. Sterry. Penetration of titanium
dioxide microparticles in a sunscreen formulation into the horny
layer and the follicular orifice. Skin Pharmacol. Appl. Skin Physiol.
12:247Y256 (1999).
8. C. C. Zouboulis. Therapie der Akne mit AntiandrogenenVEine
¨
evidenzbasierte Ubersicht. J. Dtsch. Dermatol. Ges. 1:535Y546
(2003).
9. J. Fiet, R. Morville, D. Chemama, J. M. Villette, B. Gourmel, J. 29. R. Toll, U. Jacobi, H. Richter, J. Lademann, H. Schaefer, and
L. Brerault, and C. Dreux. Percutaneous absorption of 5 alpha-
dihydrotestosterone in man. I. Plasma androgen and gonadotrophin
levels in normal adult men after percutaneous administration of 5
alpha-dihydrotestosterone. Int. J. Androl. 5:586Y594 (1982).
10. R. T. Scott Jr., B. Ross, C. Anderson, and D. F. Archer.
Pharmacokinetics of percutaneous estradiol: a crossover study
using a gel and a transdermal system in comparison with oral
micronized estradiol. Obstet. Gynecol. 77:758Y764 (1991).
11. F. Iraji, A. Momeni, S. M. Naji, and A. H. Siadat. The efficacy of
topical cyproterone acetate alcohol lotion versus placebo in the
treatment of the mild to moderate acne vulgaris: a double blind
study. Dermatol. Online J. 12:26, 2006 (2006).
U. Blume-Peytavi. Penetration profile of microspheres in follic-
ular targeting of terminal hair follicles. J. Invest. Dermatol.
123:168Y176 (2004).
30. A. Gysler, B. Kleuser, W. Sippl, K. Lange, H. C. Korting, H. D.
Ho¨ltje, and M. Scha¨fer-Korting. Skin penetration and metabo-
lism of topical glucocorticoids in reconstructed epidermis and in
excised human skin. Pharm. Res. 16:1386Y1391 (1999).
31. A. Gysler, K. Lange, H. C. Korting, and M. Scha¨fer-Korting.
Prednicarbate biotransformation in human foreskin keratino-
cytes and fibroblasts. Pharm. Res. 14:793Y797 (1997).
32. M. M. Bouton, D. Lecaque, J. Secchi, and C. Tournemine. Effect
of a new topically active antiandrogen (RU 38882) on the rat